Drug from Moss: Greenovation is allowed to start clinical trial for moss-aGal

As the Heilbronn based biotechnological company Greenovation announced recently, it has permission from the German Federal Institute for Drugs and Medical Devices to start a phase I clinical trial in Europe for its first drug candidate moss-aGal. The protein could be used as an enzyme replacement therapy for patients who suffer from Fabry disease, a rare genetic lysosomal storage disorder.

This milestone validates our BryoTechnology approach, confirming that it can serve as a production system for biopharmaceuticals”, commented CEO Dr. Thomas Fischmuth on the decision of Germany’s regulatory authority. “We have reached this goal through many years of hard work from all of our team.”


Greenovation has developed a unique technology to produce biopharmaceuticals from moss. Source: Greenovation


Moss-aGal is a recombinant form of human alpha galactosidase. Greenovation has used its proprietary BryoTechnology to express the moss-aGal protein in Physcomitrella patens. The technology attaches mannose molecules to the surface of the moss aGal protein. This improves the uptake of the proteins in the human body, mediated via mannose receptors on cell surfaces. As demonstrated by preclinical studies, this novel approach is very effective.


Moss-aGal is manufactured in the moss system Physcomitrella patens. Source: Greenovation

Fabry disease is caused by an inborn deficiency of the alpha-galactosidase (aGal) enzyme. In healthy persons aGal breaks down a specific fatty acid, globotriaosylceramide (Gb3). In patients with Fabry disease, however, Gb3 is accumulating continuously within the cells. Severe symptoms like pain and heart, skin and kidney complications occur, which can lead to organ failure. The missing enzyme can be replaced with regular intravenous administrations of a biopharmaceutically produced substitute as the world’s first moss-produced drug candidate with its promising potential could it be in the future.

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.